A Complete Roadmap for Measuring and Modeling How Your Heart Ages

Cardiovascular aging is not a single process but an intricate convergence of molecular, cellular, and systemic changes that progressively undermine heart and vascular function. This invited spotlight review, published in Cardiovascular Research, provides a detailed framework for understanding, measuring, and ultimately modeling how the cardiovascular system ages — an increasingly urgent task as global life expectancy rises and age-related cardiovascular conditions become the dominant driver of morbidity and mortality.

The review opens with telomere biology. Leukocyte telomere length (LTL) has emerged as one of the most accessible and replicated biomarkers of biological aging. A meta-analysis of 14 studies covering more than 200,000 participants found a linear inverse association between LTL and coronary artery disease (CAD) risk, with each 1 kb increase in telomere length associated with approximately a 23% reduction in coronary heart disease risk. A UK Biobank analysis of ~403,000 individuals without pre-existing CVD showed that those in the lowest LTL quartile had significantly higher incidence of sudden cardiac death, coronary events, and heart failure hospitalization. A separate UK Biobank MR study in over 470,000 participants estimated that shorter telomeres could reduce lifespan by up to 2.5 years. At the myocardial level, cardiomyocytes from heart failure patients show shorter telomeres and upregulation of the transcription factor FOXC1, mechanistically linking telomere attrition to contractile dysfunction via chromatin remodeling.

The review makes an important distinction between nuclear and mitochondrial functions of TERT (Telomerase Reverse Transcriptase). Using novel mouse models in which TERT was confined exclusively to either the nucleus or mitochondria, researchers demonstrated that mitochondrial — not nuclear — TERT is necessary and sufficient to maintain complex I activity and protect against ischemia/reperfusion cardiac injury. This finding reframes TERT as a broader guardian of mitochondrial health, not merely a telomere maintenance enzyme. The plant extract TA-65 (from Astragalus membranaceus) is noted as a pharmacological activator of telomerase that has shown preclinical efficacy in this pathway.

Cellular senescence occupies a central section of the review. Senescent cells accumulate in aged cardiovascular tissues and secrete a pro-inflammatory cocktail — the senescence-associated secretory phenotype (SASP) — that propagates dysfunction to neighboring cells. The review details detection methods including p16, p21, SA-β-galactosidase staining, and emerging liquid biopsy approaches measuring circulating SASP factors such as GDF-15, IL-6, and IL-18. Epigenetic clocks, particularly Horvath's and Levine's PhenoAge, are discussed as translational tools that capture biological age acceleration beyond chronological age and correlate with cardiovascular risk.

For clinical measurement, the review catalogs a hierarchy of tools: non-invasive markers (pulse wave velocity for arterial stiffness, flow-mediated dilation for endothelial function), cardiac imaging (cardiac MRI for structural remodeling, echocardiographic strain analysis), and circulating biomarkers (high-sensitivity CRP, NT-proBNP, troponin, and multi-protein aging clocks). The authors then argue compellingly that no single biomarker suffices — the future lies in integrating these heterogeneous data streams. They highlight machine learning models trained on UK Biobank data that predict biological cardiovascular age from ECG waveforms alone, and deep learning applied to retinal fundus images to extract vascular aging signatures. These AI approaches, the authors propose, could transform personalized cardiovascular risk stratification and guide targeted anti-aging interventions.